In a new practice advisory, an international team of experts discussed the use of gadolinium-based contrast agents (GBCAs), an alternative to iodinated contrast media, in interventional pain ...
June 9, 2006 — The U.S. Food and Drug Administration (FDA) has notified healthcare professionals regarding the potential risk for nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy ...
PRINCETON, N.J., March 31, 2017 /PRNewswire/ -- Guerbet LLC., subsidiary of Guerbet Group (FR0000032526 GBT), the global specialist in contrast products and solutions for medical imaging, takes note ...
Mayo Clinic research finds direct evidence of gadolinium deposition in neuronal tissues following intravenous administration of gadolinium-based contrast agents used in MRI exams. The findings were ...
VUEWAY injection is highly stable and shows the highest relaxivity among gadolinium-based contrast agents available for clinical use i VUEWAY injection is approved for use in adult and pediatric ...
PRINCETON, N.J., Feb. 20, 2026 /PRNewswire/ -- Guerbet, a global specialist in contrast media and solutions for medical imaging, is pleased to announce that the U.S. Food and Drug Administration (FDA) ...
Gadopiclenol carries a Boxed Warning associated with an increased risk of nephrogenic systemic fibrosis among patients with impaired elimination of the drugs. The approval of gadopiclenol was based on ...
New research finds direct evidence of gadolinium deposition in neuronal tissues following intravenous administration of gadolinium-based contrast agents used in MRI exams. "Despite evidence that trace ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results